8V17 | pdb_00008v17

HIV-CA Disulfide linked Hexamer with inhibitor bound - exploration of a benzothiazole


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.50 Å
  • R-Value Free: 
    0.171 (Depositor), 0.172 (DCC) 
  • R-Value Work: 
    0.142 (Depositor), 0.142 (DCC) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 8V17

Ligand Structure Quality Assessment 


This is version 1.0 of the entry. See complete history

Literature

"Pseudosubstrate Envelope"/Free Energy Perturbation-Guided Design and Mechanistic Investigations of Benzothiazole HIV Capsid Modulators with High Ligand Efficiency.

Xu, S.Wang, S.Zhou, Y.Foley, N.Sun, L.Walsham, L.Tang, K.Shi, D.Shi, X.Zhang, Z.Jiang, X.Gao, S.Liu, X.Pannecouque, C.Goldstone, D.C.Dick, A.Zhan, P.

(2024) J Med Chem 67: 19057-19076

  • DOI: https://doi.org/10.1021/acs.jmedchem.4c01544
  • Primary Citation Related Structures: 
    8V17

  • PubMed Abstract: 

    Based on our proposed "pseudosubstrate envelope" concept, 25 benzothiazole-bearing HIV capsid protein (CA) modulators were designed and synthesized under the guidance of free energy perturbation technology. The most potent compound, IC-1k , exhibited an EC 50 of 2.69 nM against HIV-1, being 393 times more potent than the positive control PF74. Notably, IC-1k emerged as the highest ligand efficiency (LE = 0.32) HIV CA modulator, surpassing that of the approved drug lenacapavir (LE = 0.21). Surface plasmon resonance assay and crystallographic analysis confirmed that IC-1k targeted HIV-1 CA within the chemical space of the "pseudosubstrate envelope". Further mechanistic studies revealed a dual-stage inhibition profile: IC-1k disrupted early-stage capsid-host-factor interactions and promoted late-stage capsid misassembly. Preliminary pharmacokinetic evaluations demonstrated significantly improved metabolic stability in human liver microsomes for IC-1k ( T 1/2 = 91.3 min) compared to PF74 ( T 1/2 = 0.7 min), alongside a favorable safety profile. Overall, IC-1k presents a promising lead compound for further optimization.


  • Organizational Affiliation
    • Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan, Shandong 250012, PR China.

Macromolecule Content 

  • Total Structure Weight: 26.05 kDa 
  • Atom Count: 1,921 
  • Modeled Residue Count: 219 
  • Deposited Residue Count: 229 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Spacer peptide 1229Human immunodeficiency virus 1Mutation(s): 4 
Gene Names: gag
UniProt
Find proteins for Q72497 (Human immunodeficiency virus type 1)
Explore Q72497 
Go to UniProtKB:  Q72497
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ72497
Sequence Annotations
Expand
Reference Sequence

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.50 Å
  • R-Value Free:  0.171 (Depositor), 0.172 (DCC) 
  • R-Value Work:  0.142 (Depositor), 0.142 (DCC) 
Space Group: P 6
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 90.902α = 90
b = 90.902β = 90
c = 56.468γ = 120
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2024-12-11
    Type: Initial release